Breaking News, Collaborations & Alliances

Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact

MolMed to support the development and manufacture of vectors and drug products for Orchard’s investigational hematopoietic stem cell (HSC) gene therapies.

By: Contract Pharma

Contract Pharma Staff

Orchard Therapeutics and MolMed S.p.A have extended their collaboration initiated in April 2018, through June 2025. MolMed will continue to support activities related to the development and manufacture of vectors and drug products for several of Orchard’s investigational ex vivo hematopoietic stem cell (HSC) gene therapies, including OTL-200 for metachromatic leukodystrophy (MLD), OTL-103 for Wiskott Aldrich syndrome (WAS), and OTL-203 for mucopolysaccharidosis type I (MPS-I). MolMed is the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters